CASE REPORT
===========

We report a 73-year-old woman under post-surgical chemotherapy (breast ductal carcinoma) who presented with transudation and pain on the lower limbs 20 days after the first cycle with doxorubicin and cyclophosphamide and no improvement with furosemide.

Due to treatment failure after four cycles of adjuvant regimen, the patient was started on herceptin and paclitaxel. From the 45^th^ day of this new regimen, we observed the development of an edema and considerable erythema on the hands, wrists, legs, and feet. We also observed desquamation, ulceration, vesicopustules, and intense burning sensation. Little improvement was observed after analgesia, topical corticosteroids and cephalexin ([Figures 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}).

Figure 1Erythema and acral edema on the lower limbs, with flaking and areas of ulceration

Figure 2Detail of scaly erythematous lesions of the posterior region of the ankles with areas of ulceration and vesicopustules

Laboratory tests were normal. Histopathological examination showed areas of epidermal necrosis with small clefts, keratinocyte apoptosis, parakeratosis foci, and basal vacuolar degeneration with extensive involvement of the acrosyringium without squamous syringometaplasia.

We opted for hospitalization, suspension of chemotherapy, and administration of opioids, prednisone (0.5 mg/kg), potassium permanganate compresses, and application of occlusive dressing with fludroxycortide. The patient was discharged five days later with significant improvement in pain and lesions.

DISCUSSION
==========

Hand-foot syndrome (HFS) - or palmar-plantar erythrodysesthesia, acral erythema, or Burgdorf reaction - is an adverse event of many chemotherapeutic agents, especially liposomal doxorubicin, capecitabine, 5-fluorouracil, cytarabine, docetaxel, sorafenib, sunitinib, cyclophosphamide, etoposide, vinorelbine, methotrexate, hydroxyurea, tegafur, mercaptopurine, and paclitaxel.^[@r1],[@r2]^

After alopecia and mucositis, HFS is the most common adverse dermatologic reaction to chemotherapy, with an incidence of 3%-64%. The highest incidences occur with doxorubicin (40%-50%) and capecitabine (50%-60%). The risk of HFS seems to be dose-dependent: formulations that prolong the serum level or that concentrate the drug at the affected sites have the highest association rates.^[@r1]^

The pathogenesis of HFS is not known. It is believed to be a toxic reaction due to the local accumulation of the drug with consequent degeneration and necrosis of the sweat glands. That is because its microscopic features resemble squamous eccrine syringometaplasia and neutrophilic eccrine hidradenitis patterns.^[@r2],[@r3]^

HFS presents with prodromal dysesthesia and palmar-plantar tingling. Within days, the reaction progresses to burning pain, well-defined edema and erythema with a tendency to symmetry and flaking, and limitation of daily activities. Extreme cases involve ulceration and blisters, palmoplantar keratoderma, nail dystrophy, inflammation of actinic keratoses, and may affect the folds of the skin (axillary, inguinal, perineal, and inframammary).^[@r1],[@r2],[@r4]-[@r6]^

Different classifications grade the severity of HFS. The two most commonly used criteria are provided by the World Health Organization and by the National Cancer Institute ([Chart 1](#t1){ref-type="table"}).^[@r7]^

###### 

Clinical description of severity for hand-foot syndrome according to NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) and WHO (World Health Organization) and associated histologic findings

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Grade   NCI-CTCAE (version 4.03)                                  WHO                                                 Histological findings
  ------- --------------------------------------------------------- --------------------------------------------------- -------------------------
  1       minimal skin changes OR dermatitis (e.g. erythema,\       Dysesthesia/paresthesia, tingling in hands and\     Dilated vessels in the\
          edema, or hyperkeratosis) NO pain                         feet                                                superficial dermal\
                                                                                                                        plexus

  2       Cutaneous lesions (e.g. flaking, blistering, bleeding,\   Discomfort when holding objects and walking,\        
          swelling, and hyperkeratosis) WITH pain, but\             painless swelling, or erythema                      
          with minimum limitation                                                                                       

  3       Ulcerative dermatitis or serious painful cutaneous\       Painful erythema and swelling of the palms and\     Isolated keratinocytes\
          lesions (e.g. flaking, blistering, bleeding, swelling,\   soles; erythema and periungual swelling             necrosis in the\
          and hyperkeratosis) interfering with function and\                                                            outer layers of the\
          self-care                                                                                                     epidermis

  4                                                                 Desquamation, ulceration, blistering, and severe\   Complete epidermal\
                                                                    pain                                                necrosis
  -----------------------------------------------------------------------------------------------------------------------------------------------

There are no longitudinal studies that explore specific treatments. Suggestive therapy include reducing chemotherapy dosage, increasing the interval between cycles, or even stopping chemotherapy, which would lead to remission of the picture in up to two weeks. Dressings, rigorous analgesia, emollients, cold compresses, and potent topical corticosteroids associated with emollients or systemic corticosteroids are reported as efficient. Cooling of the hands and feet and use of emollients and antiperspirants (aluminum chloride hydroxide) during infusions can prevent the reaction. Oral pyridoxine showed no preventive efficacy in HFS.^[@r2],[@r8]-[@r10]^

With an aging population and greater access to health care and oncological diagnosis, cutaneous reactions to chemotherapy should become more frequent. Prevention, identification, and early intervention is essential for clinicians in cases of HFS.
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